192 related articles for article (PubMed ID: 31455338)
21. Increased brachial intima-media thickness is associated with circulating levels of asymmetric dimethylarginine in patients with COPD.
Urban MH; Eickhoff P; Funk GC; Burghuber OC; Wolzt M; Valipour A
Int J Chron Obstruct Pulmon Dis; 2017; 12():169-176. PubMed ID: 28115840
[TBL] [Abstract][Full Text] [Related]
22. Change of Serum Inflammatory Cytokines Levels in Patients With Chronic Obstructive Pulmonary Disease, Pneumonia and Lung Cancer.
Chen J; Li X; Huang C; Lin Y; Dai Q
Technol Cancer Res Treat; 2020; 19():1533033820951807. PubMed ID: 33111646
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of ADAMTS-13 on concealed chronic renal failure in COPD patients.
Zeng M; Chen Q; Liang W; He W; Zheng H; Huang C
Int J Chron Obstruct Pulmon Dis; 2017; 12():3495-3501. PubMed ID: 29255356
[TBL] [Abstract][Full Text] [Related]
24. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease.
Valipour A; Schreder M; Wolzt M; Saliba S; Kapiotis S; Eickhoff P; Burghuber OC
Clin Sci (Lond); 2008 Oct; 115(7):225-32. PubMed ID: 18307413
[TBL] [Abstract][Full Text] [Related]
25. Can we predict the prognosis of COPD with a routine blood test?
Xiong W; Xu M; Zhao Y; Wu X; Pudasaini B; Liu JM
Int J Chron Obstruct Pulmon Dis; 2017; 12():615-625. PubMed ID: 28243079
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
Thomsen M; Dahl M; Lange P; Vestbo J; Nordestgaard BG
Am J Respir Crit Care Med; 2012 Nov; 186(10):982-8. PubMed ID: 22983959
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
Thomsen M; Ingebrigtsen TS; Marott JL; Dahl M; Lange P; Vestbo J; Nordestgaard BG
JAMA; 2013 Jun; 309(22):2353-61. PubMed ID: 23757083
[TBL] [Abstract][Full Text] [Related]
28. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients.
Lim JU; Yeo CD; Rhee CK; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
Int J Chron Obstruct Pulmon Dis; 2019; 14():929-938. PubMed ID: 31118602
[No Abstract] [Full Text] [Related]
29. Alterations of the neutrophil-lymphocyte ratio during the period of stable and acute exacerbation of chronic obstructive pulmonary disease patients.
Taylan M; Demir M; Kaya H; Selimoglu Sen H; Abakay O; Carkanat Aİ; Abakay A; Tanrikulu AC; Sezgi C
Clin Respir J; 2017 May; 11(3):311-317. PubMed ID: 26096858
[TBL] [Abstract][Full Text] [Related]
30. Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review.
Pascual-González Y; López-Sánchez M; Dorca J; Santos S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3651-3662. PubMed ID: 30464448
[TBL] [Abstract][Full Text] [Related]
31. Anti-
Banerjee S; Bhattacharyya P; Mitra S; Kundu S; Panda S; Chatterjee IB
Int J Chron Obstruct Pulmon Dis; 2017; 12():1847-1856. PubMed ID: 28684907
[TBL] [Abstract][Full Text] [Related]
32. Skin condition and its relationship to systemic inflammation in chronic obstructive pulmonary disease.
Majewski S; Pietrzak A; Tworek D; Szewczyk K; Kumor-Kisielewska A; Kurmanowska Z; Górski P; Zalewska-Janowska A; Piotrowski WJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():2407-2415. PubMed ID: 28860735
[TBL] [Abstract][Full Text] [Related]
33. What is the impact of different spirometric criteria on the prevalence of spirometrically defined COPD and its comorbidities? Results from the population-based KORA study.
Karrasch S; Brüske I; Smith MP; Thorand B; Huth C; Ladwig KH; Kronenberg F; Heinrich J; Holle R; Peters A; Schulz H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1881-94. PubMed ID: 27574413
[TBL] [Abstract][Full Text] [Related]
34. Systemic and Tumor Th1 and Th2 Inflammatory Profile and Macrophages in Lung Cancer: Influence of Underlying Chronic Respiratory Disease.
Mateu-Jimenez M; Curull V; Pijuan L; Sánchez-Font A; Rivera-Ramos H; Rodríguez-Fuster A; Aguiló R; Gea J; Barreiro E
J Thorac Oncol; 2017 Feb; 12(2):235-248. PubMed ID: 27793775
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.
Waschki B; Watz H; Holz O; Magnussen H; Olejnicka B; Welte T; Rabe KF; Janciauskiene S
Int J Chron Obstruct Pulmon Dis; 2017; 12():981-987. PubMed ID: 28356730
[TBL] [Abstract][Full Text] [Related]
36. Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers.
Singh S; Verma SK; Kumar S; Ahmad MK; Nischal A; Singh SK; Dixit RK
Immunol Lett; 2018 Apr; 196():1-10. PubMed ID: 29329680
[TBL] [Abstract][Full Text] [Related]
37. Identification of thyroxine-binding globulin as a candidate plasma marker of chronic obstructive pulmonary disease.
Diao W; Shen N; Du Y; Sun X; Liu B; Xu M; He B
Int J Chron Obstruct Pulmon Dis; 2017; 12():1549-1564. PubMed ID: 28579773
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients.
Sakurai K; Chubachi S; Irie H; Tsutsumi A; Kameyama N; Kamatani T; Koh H; Terashima T; Nakamura H; Asano K; Betsuyaku T
BMC Pulm Med; 2018 May; 18(1):65. PubMed ID: 29720140
[TBL] [Abstract][Full Text] [Related]
39. The clinical implication of serum cyclophilin A in patients with chronic obstructive pulmonary disease.
Zhang M; Tang J; Yin J; Wang X; Feng X; Yang X; Shan H; Zhang Q; Zhang J; Li Y
Int J Chron Obstruct Pulmon Dis; 2018; 13():357-363. PubMed ID: 29403273
[TBL] [Abstract][Full Text] [Related]
40. Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease.
Vaguliene N; Zemaitis M; Lavinskiene S; Miliauskas S; Sakalauskas R
BMC Immunol; 2013 Aug; 14():36. PubMed ID: 23919722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
